Literature DB >> 25704482

Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.

F Di Fabio1, W Aston1, F Mohamed1, K Chandrakumaran1, T Cecil1, B Moran1.   

Abstract

AIM: Elevation of the preoperative tumour markers in pseudomyxoma peritonei (PMP) is common and is a risk factor for recurrence. There has, however, been no documentation of the effect of complete tumour removal on tumour markers levels after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of the study was to compare the tumour markers 7 days after surgery in patients with elevated preoperative levels.
METHOD: This was an observational prospective study of patients with PMP of appendiceal origin treated in one of the UK National Referral Centres for this condition. Thirty patients [median age = 61 (range: 31-74) years; six men] with an elevated preoperative level of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA-125) and/or carbohydrate antigen 19-9 (CA19-9) underwent repeated estimation, 7 days after CRS and HIPEC for PMP.
RESULTS: The median preoperative CEA level of 12 μg/l fell to 0.75 μg/l postoperatively (P < 0.0001), CA-125 fell from 45 to 31 kU/l (P = 0.183) and CA19-9 fell from 134 to 37 kU/l (P = 0.003). The CEA was raised in 22 (73%) of 30 patients preoperatively and in two (7%) of 30 patients 7 days after surgery (P < 0.0001). The corresponding data for CA-125 were 18 (60%) and 13 (43%) (P = 0.196) and for CA19-9 they were 24 (80%) and 16 (53%) (P = 0.028).
CONCLUSION: This is the first documentation of a reduction or normalization of CEA 7 days after CRS, but not for CA19-9 or CA-125. This may indicate completeness of surgical resection and could aid selection for adjuvant therapy and predict prognosis. Long-term follow-up is, however, necessary to determine the significance of this observation. Colorectal Disease
© 2015 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Tumour markers; appendix tumour; carbohydrate antigen 125; carbohydrate antigen 19-9; carcinoembryonic antigen; pseudomyxoma peritonei

Mesh:

Substances:

Year:  2015        PMID: 25704482     DOI: 10.1111/codi.12924

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  4 in total

1.  Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative.

Authors:  Mohammad Y Zaidi; Rachel M Lee; Adriana C Gamboa; Shelby Speegle; Jordan M Cloyd; Charles Kimbrough; Travis Grotz; Jennifer Leiting; Keith Fournier; Andrew J Lee; Sean Dineen; Sophie Dessureault; Kaitlyn J Kelly; Nikhil V Kotha; Callisia Clarke; T Clark Gamblin; Sameer H Patel; Tiffany C Lee; Ryan J Hendrix; Laura Lambert; Sean Ronnekleiv-Kelly; Courtney Pokrzywa; Andrew M Blakely; Byrne Lee; Fabian M Johnston; Nadege Fackche; Maria C Russell; Shishir K Maithel; Charles A Staley
Journal:  Ann Surg Oncol       Date:  2019-10-10       Impact factor: 5.344

Review 2.  The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies.

Authors:  Mackenzie C Morris; Jordan M Cloyd; John Hays; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2020-08-17       Impact factor: 3.452

3.  Preserving fertility in pseudomyxoma peritonei, a novel approach.

Authors:  Lisa A Sheehan; Akash M Mehta; Saladin Sawan; Sanjeev P Dayal; Faheez Mohamed; Brendan J Moran; Tom D Cecil
Journal:  Pleura Peritoneum       Date:  2017-01-19

Review 4.  Approach to pseudomyxoma peritonei.

Authors:  Syed Ali Rizvi; Wajahat Syed; Ravi Shergill
Journal:  World J Gastrointest Surg       Date:  2018-08-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.